BioCryst to Present Peramivir Data at the 50th Annual ICAAC Meeting

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Sep 15, 2010 - BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 50th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) in Boston, Massachusetts.

The data from the following human safety studies will be presented during a poster session scheduled for Wednesday, September 15, 2010 from 9:00-11:00 a.m. Eastern Time. The two posters to be presented during the session include:

 

  • Presentation Number A1-2001: “No Pharmacokinetic Interactions Observed between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans,” which concludes that there is no evidence of a pharmacokinetic interaction between i.v. peramivir (600 mg) with oral oseltamivir (75 mg) or oral rimantadine (100 mg) when administered simultaneously in hospitalized patients with influenza
  • Presentation Number A1-2000: “Intravenous Peramivir was not Associated with Repolarization Abnormalities in a Thorough QT/QTc Electrocardiographic Study,” which concludes that i.v. peramivir administered at two single doses (600 mg and 1200 mg) was not associated with QTc prolongation or other repolarization abnormalities, and that peramivir was generally safe and well-tolerated

Copies of the abstracts are available and can be viewed online through the ICAAC Web site at http://www.icaac.org/.

About Peramivir

Peramivir is a potent, intravenously administered investigational anti-viral agent that rapidly delivers high plasma concentrations to the sites of infection. Discovered by BioCryst, peramivir inhibits the interactions of influenza neuraminidase, an enzyme that is critical to the spread of influenza within the host. Peramivir is an inhibitor of influenza A and B viruses, including strains of influenza viruses that may be resistant to available neuraminidase inhibitors. In January 2006, BioCryst received United States Food and Drug Administration (FDA) Fast Track designation for peramivir. The availability of an intravenous (i.v.) neuraminidase inhibitor may be important in treating patients hospitalized with severe and potentially life-threatening influenza by ensuring that the appropriate dose is administered, which may be a concern with currently available oral or inhaled anti-influenza agents.

Peramivir currently is being developed under a $180 million contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS).

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds that are in late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Additionally, BioCryst has a third product candidate, BCX4208—a next generation PNP inhibitor—in mid-stage trials for the treatment of gout. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information please visit BioCryst's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

Contact: BioCryst Pharmaceuticals, Inc.
Investors
Robert Bennett, 919-859-7910
or
Media
Catherine Collier Kyroulis, 212-301-7174

 

Posted: September 2010

View comments

Hide
(web3)